What is the recommended treatment regimen for Mycobacterium paragordona infection?

Mycobacterium paragordonae (MPG) — Treatment Recommendation

Bold recommendation: Treat confirmed Mycobacterium paragordonae infection with a rifampin–ethambutol backbone plus a macrolide (clarithromycin or azithromycin) for at least 12 months after culture conversion, mirroring M. gordonae/M. kansasii regimens to minimize morbidity, mortality, and preserve quality of life. 1, 2

• Rationale and highest-quality guidance:
  • No dedicated MPG guideline exists; MPG belongs to the M. gordonae clade. The most recent, highest-quality ATS/ERS/ESCMID/IDSA guideline supports rifampin + ethambutol with either isoniazid or a macrolide for rifampin-susceptible M. kansasii, with at least 12 months of therapy after culture conversion; macrolide is acceptable in place of isoniazid and parenteral aminoglycosides are generally not indicated due to toxicity and lack of added benefit in most cases 1, 2.
  • BTS 2017 concurs: rifampin + ethambutol + isoniazid or a macrolide; treat ≥12 months after conversion 3.
  • A 2024 MPG case used clarithromycin + levofloxacin + rifampin + ethambutol with rapid radiographic response, aligning with ATS/IDSA M. gordonae-style therapy; however, single-case evidence is low quality and fluoroquinolone is second-line by guidelines unless rifampin resistance or intolerance exists 4, 2.

Step-by-step algorithm (prioritizing outcomes)

1. Confirm true disease, not contamination

   • Require compatible clinical/radiographic syndrome plus microbiologic confirmation (culture/PCR/mNGS) from sterile site or repeated respiratory isolates; M. gordonae-clade organisms are frequent tap-water contaminants—avoid treating colonization to prevent drug toxicity/QOL harm 5.

2. Baseline testing before therapy

   • Drug interactions/toxicity risk review for rifampin and macrolides; baseline LFTs, CBC, renal function; baseline visual acuity and color testing for ethambutol to protect QOL.

3. First-line oral regimen (rifampin-susceptible)

   • Rifampin 10 mg/kg (max 600 mg) daily
   • Ethambutol 15 mg/kg daily
   • Plus ONE of:
     • Isoniazid 300 mg daily with pyridoxine 25–50 mg daily, or
     • Macrolide: clarithromycin 500 mg twice daily or azithromycin 250–500 mg daily
   • Choose macrolide rather than INH if drug–drug interactions and tolerance favor it or if INH MIC is high; both options acceptable with very low-certainty but consistent guideline support 1, 3, 2.

4. Duration

   • Continue until ≥12 months of consecutive negative cultures after conversion (not a fixed calendar course) to reduce relapse and downstream morbidity 1, 3, 2.

5. Monitoring

   • Monthly symptom check and sputum cultures until conversion, then at least every 1–2 months during therapy; LFTs periodically; vision checks for ethambutol 5.

6. Special situations

   • Suspected/confirmed rifampin resistance or intolerance: Use ethambutol + macrolide + fluoroquinolone (prefer moxifloxacin) as second-line; avoid routine aminoglycosides unless severe disease or no rifamycin possible due to toxicity risks 1, 2.
   • HIV/ART: Construct ART compatible with rifampin or consider rifabutin-based adjustments per TB–ART interaction resources; if rifamycins cannot be used, prioritize macrolide + moxifloxacin + ethambutol and extend monitoring due to higher failure risk 5, 1, 2.

Nuances, caveats, pitfalls

• MPG evidence is sparse; strongest recent guidance comes from NTM guidelines for closely related species (M. kansasii and M. gordonae-clade). Use macrolide-containing rifampin–ethambutol regimens as the standard, reserving fluoroquinolones for second-line needs to limit toxicity and resistance, thereby safeguarding QOL and outcomes 1, 2.
• Do not add routine amikacin/streptomycin—higher adverse events without proven benefit in typical pulmonary disease 1, 2.
• Avoid treating single, low-burden respiratory isolates without clinical–radiographic disease—common contamination can lead to unnecessary toxicity and worsened QOL 5.
• A 2024 case suggests good response to clarithromycin + levofloxacin + rifampin + ethambutol; however, as single-case, it should not override guideline-first approaches; consider fluoroquinolone if rifampin cannot be used or resistance/intolerance occurs 4, 2.

Practical regimen example (adult, rifampin-susceptible MPG pulmonary disease)

• Rifampin 600 mg daily + Ethambutol 15 mg/kg daily + Clarithromycin 500 mg BID (or Azithromycin 250–500 mg daily)
• Treat until 12 months beyond culture conversion; monitor monthly cultures and toxicity 1, 3, 2.